Content about Royalties

October 23, 2013

Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

NEWARK, Calif. — Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.

The drug maker announced that it had sold its interest in the Type 2 diabetes therapeutic area to PDL for $240.5 million, which it plans to use to acquire rights to products it said would drive long-term growth and build on its expertise in pain and neurology.

July 19, 2013

Royalty Pharma has hired Marshall Urist as VP research and investments, the company said Friday.

NEW YORK — Royalty Pharma has hired Marshall Urist as VP research and investments, the company said Friday.

Royalty, which invests in royalty interests in drugs, hired Urist from Morgan Stanley, where he worked most recently as executive director and the senior biotechnology analyst.

"We are excited to have Marshall join our team," Royalty founder and CEO Pablo Legorreta said. "He has had a distinguished career on Wall Street, and this experience, coupled with his deep analytical skills, make him an excellent addition to Royalty Pharma."

June 18, 2013

Royalty Pharma will not buy Irish drug maker Elan Corp., the company said Tuesday.

NEW YORK — Royalty Pharma will not buy Irish drug maker Elan Corp., the company said Tuesday.

Royalty said it would withdraw a request for a review by the Irish Takeover Panel after Elan shareholders voted in favor of a share buyback. Elan said last week that it would begin a process of selling itself to Royalty, which had previously offered $13 per share for the company.

June 14, 2013

Irish drug maker Elan Corp. said Friday it was looking to sell itself off to a New York-based company that invests in drug royalties after rejecting a previous offer.

DUBLIN — Irish drug maker Elan Corp. said Friday it was looking to sell itself off to a New York-based company that invests in drug royalties after rejecting a previous offer.

The company said it would start a process to be acquired by Royalty Pharma, but that shareholders should not put their shares up for sale into another, hostile takeover attempt by Royalty, in which Royalty offered more than $7.7 billion, or $13 per share, plus $2.50 in milestone payments. Elan has rejected that offer, made last week.

February 26, 2013

A privately owned drug maker in New York is offering $6.5 billion for Irish drug maker Elan Corp., but hasn't heard back from it, according to published reports.

NEW YORK — A privately owned drug maker in New York is offering $6.5 billion for Irish drug maker Elan, but hasn't heard back from it, according to published reports.

The Associated Press reported that Royalty Pharma's $11-per-share offer for Elan represented a 4% premium over its closing price Friday. Royalty buys royalty interests in drug products that are in late-stage development or have already entered the market, but doesn't develop or market drugs of its own, the AP reported.

February 8, 2013

Elan will sell the rights to its drug for multiple sclerosis to partnering company Biogen Idec for $3.25 billion plus royalties, the Irish drug maker said.

DUBLIN - Elan Corp. will sell the rights to its drug for multiple sclerosis to partnering company Biogen Idec for $3.25 billion plus royalties, the Irish drug maker said.

April 3, 2012

Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.

NEW YORK — Forest Labs has bought rights to a drug used for high blood pressure that it had marketed with a Johnson & Johnson subsidiary, thus eliminating the need to pay future royalties.

Forest announced Monday that it had bought all U.S. and Canadian intellectual property related to Bystolic (nebivolol) for $357 million from Janssen Pharmaceutica NV on Friday.

August 15, 2011

Elizabeth Arden has amended its long-term license agreement with Liz Claiborne to acquire the trademarks for the Curve fragrance brands and selected other smaller fragrance brands.

NEW YORK — Elizabeth Arden has amended its long-term license agreement with Liz Claiborne to acquire the trademarks for the Curve fragrance brands and selected other smaller fragrance brands.

The amendment also includes a lower effective royalty rate for the remaining licensed fragrance brands, including Juicy Couture and Lucky Brand fragrances, reduces the future minimum guaranteed royalties for the term of the license and requires a pre-payment of royalties for the remainder of calendar 2011.

April 13, 2011

The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

LINCOLNSHIRE, Ill. — The Food and Drug Administration has accepted a regulatory approval application for a topical treatment for low testosterone made by Teva Pharmaceuticals and BioSante Pharmaceuticals, BioSante said Wednesday.

The two companies said the FDA had accepted their application for Bio-T-Gel and expected to complete its review by mid-November.

February 7, 2011

Salix Pharmaceuticals and Progenics Pharmaceuticals have entered a licensing agreement for a drug used to treat side effects of opioid use.

TARRYTOWN, N.Y. — Salix Pharmaceuticals and Progenics Pharmaceuticals have entered a licensing agreement for a drug used to treat side effects of opioid use.

The two companies signed the agreement for Relistor (methylnaltrexone bromide), an injected drug used to treat opioid-induced constipation in patients for whom laxatives haven’t worked.

September 22, 2010

Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic...

ABBOTT PARK, Ill. Drug makers Abbott and Reata Pharmaceuticals have signed an agreement concerning a drug for chronic kidney disease.

 

The two companies said Thursday that they would develop and commercialize bardoxolone methyl, currently in mid-stage clinical trials.

 

 

August 29, 2010

A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia...

SAN DIEGO A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia treatment.

Somaxon Pharmaceuticals and Procter & Gamble announced their co-promotion agreement for Silenor, in which Somaxon's promotion of the drug will target physicans, while P&G will promote Silenor to targeted pharmacies.

March 30, 2010

A licensing agreement between AstraZeneca and Rigel Pharmaceuticals for a rheumatoid arthritis treatment has gone...